DT2216
DT2216 has been studied in 2 papers since 2022: none in people yet, 1 in cells, 1 review. No study of it in people or animals has been published yet. The newest paper, Dec 3, 2024: “HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells”.
- Cells1
Latest
Cell Death and Differentiation
HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells
Experiments in human cellsCellular senescence